Invest
EU policy reforms and pharma investments highlight shifting industry priorities
Invest
EU policy reforms and pharma investments highlight shifting industry priorities
In a significant move to bolster the pharmaceutical landscape across Europe, the European Parliament's rapporteur has unveiled draft reforms to the proposed EU Critical Medicines Act. These reforms aim to enhance investment in domestic manufacturing and expand stockpiling measures, ensuring a steady supply of medicines across EU member states. The draft legislation broadens the definition of "medicines of common interest" and extends investment incentives beyond just critical medicines. It also introduces multi-winner procurement, minimum supply commitments, and an EU coordination mechanism to manage shortages. This initiative signals a shift in industry priorities, according to GlobalData, a leading data and analytics company.
EU policy reforms and pharma investments highlight shifting industry priorities
In a significant move to bolster the pharmaceutical landscape across Europe, the European Parliament's rapporteur has unveiled draft reforms to the proposed EU Critical Medicines Act. These reforms aim to enhance investment in domestic manufacturing and expand stockpiling measures, ensuring a steady supply of medicines across EU member states. The draft legislation broadens the definition of "medicines of common interest" and extends investment incentives beyond just critical medicines. It also introduces multi-winner procurement, minimum supply commitments, and an EU coordination mechanism to manage shortages. This initiative signals a shift in industry priorities, according to GlobalData, a leading data and analytics company.
Eóin Ryan, Manager of Health Economics and Market Access at GlobalData, commented on the implications of these proposals: “The proposals strengthen investment channels for both common and critical medicines and reinforce Europe’s manufacturing base. However, expanding stockpiling obligations could increase administrative and cost burdens for companies already facing tight margins.”
The discussions surrounding these reforms are set to continue into 2026, as the EU seeks to strike a balance between strategic autonomy and market efficiency. The emphasis on domestic manufacturing and stockpiling is seen as a response to recent global supply chain disruptions and the need for Europe to ensure its pharmaceutical independence.
In parallel with these policy developments, significant investments in the pharmaceutical sector are unfolding on the other side of the Atlantic. GlobalData’s Bio/Pharmaceutical Outsourcing Report highlights GSK's announcement of a massive $30 billion, five-year investment to expand its R&D and manufacturing capabilities in the United States. This investment includes $1.2 billion earmarked for advanced technologies and the construction of a new biologics flex factory in Upper Merion, Pennsylvania, slated to begin in 2026.
GSK CEO Emma Walmsley has emphasised the company's continued commitment to its UK roots, stating that GSK will keep investing over $2.3 billion annually in research and development. This dual investment strategy underscores GSK’s approach to balancing its global presence. Janet Beal, Managing Analyst for Health Economics and Market Access at GlobalData, noted: “GSK’s dual investment strategy demonstrates a clear commitment to strengthening its US footprint while maintaining confidence in its UK base. This approach reflects a broader industry trend to balance global competitiveness amid shifting policy and trade dynamics.”
The landscape of pharmaceutical investment is further enriched by FUJIFILM Biotechnologies USA's announcement of a $2 billion investment, funded by Johnson & Johnson. This investment will be used to construct a 160,000-square-foot facility at its Holly Springs site, creating approximately 120 new jobs and expanding US capacity for advanced medicines. Meanwhile, Capitol Biologics is set to offer comprehensive early-phase biologics development and GMP manufacturing services for private biotech firms and US government agencies. These services will adhere to a unified quality system aligned with FDA, EMA, and ICH standards.
The Bio/Pharmaceutical Outsourcing Report, a monthly analysis of trends affecting pharmaceutical contract manufacturing organisations (CMOs), provides insights into the latest contract manufacturing agreements, opportunities, and threats for CMOs, as well as mergers and acquisitions and emerging regulatory news.
These developments highlight a broader trend within the pharmaceutical industry, where companies are navigating a complex web of policy changes and investment opportunities to secure their positions in an increasingly competitive global market. As the EU works towards greater strategic autonomy, and companies like GSK and FUJIFILM Biotechnologies USA expand their investment portfolios, the industry is poised for transformative changes that could redefine the future of pharmaceutical manufacturing and supply.
RELATED ARTICLES
Investment insights
HarbourVest Partners unveils new private equity benchmarks highlighting long-term outperformance
In a significant update for the private equity world, HarbourVest Partners, a leading global private markets investment firm, has released its quarterly private equity benchmarks, providing ...Read more
Investment insights
Mason Stevens strengthens UHNW offering through partnership with GloryHouse
In a strategic move set to bolster its position in the ultra-high-net-worth (UHNW) sector, Mason Stevens, a prominent name in Australia's wealth management landscape, has announced a partnership with ...Read more
Investment insights
Beyond the trophy: What the Women in Finance Awards 2025 signal for strategy, talent and ROI
Australia’s Women in Finance Awards have crowned their 2025 cohort, but the real story isn’t the stage—it’s the strategy. Recognition programs now function as market barometers, signalling which ...Read more
Investment insights
Orbis Investments challenges investors to rethink assumptions in 2026
In a bold move to reshape investor perspectives, Orbis Investments has released a new report titled "Six Courageous Questions for 2026," encouraging investors to critically evaluate their assumptions ...Read more
Investment insights
Rate relief on the horizon? How a November cut could reshape Australian balance sheets
With unemployment edging up to a multi-year high, markets are weighing whether the Reserve Bank will pivot to a rate cut as early as November. For CFOs and CEOs, the real question isn’t if a cut ...Read more
Investment insights
J.P. Morgan unveils insights from the world's wealthiest families in 2025 report
In a world increasingly defined by rapid technological advancements and global uncertainties, J.P. Morgan has released its 2025 Principal Discussions Report, offering a unique glimpse into the minds ...Read more
Investment insights
RBA keeps the playbook open: how to navigate an “anything-can-happen” rate path
The Reserve Bank has kept its options open on interest rates, signalling neither cuts nor hikes are off the table. For boards and CFOs, that ambiguity is not a bug — it’s the game. With the cash rate ...Read more
Investment insights
Hotter CPI, cooler cuts: What the RBA pause means for balance sheets, pricing and 2025 strategy
A surprise upside in quarterly inflation has shifted the Reserve Bank of Australia’s calculus: a cut now looks less likely, and a prolonged plateau in rates more probable. For CFOs, that changes the ...Read more
Investment insights
HarbourVest Partners unveils new private equity benchmarks highlighting long-term outperformance
In a significant update for the private equity world, HarbourVest Partners, a leading global private markets investment firm, has released its quarterly private equity benchmarks, providing ...Read more
Investment insights
Mason Stevens strengthens UHNW offering through partnership with GloryHouse
In a strategic move set to bolster its position in the ultra-high-net-worth (UHNW) sector, Mason Stevens, a prominent name in Australia's wealth management landscape, has announced a partnership with ...Read more
Investment insights
Beyond the trophy: What the Women in Finance Awards 2025 signal for strategy, talent and ROI
Australia’s Women in Finance Awards have crowned their 2025 cohort, but the real story isn’t the stage—it’s the strategy. Recognition programs now function as market barometers, signalling which ...Read more
Investment insights
Orbis Investments challenges investors to rethink assumptions in 2026
In a bold move to reshape investor perspectives, Orbis Investments has released a new report titled "Six Courageous Questions for 2026," encouraging investors to critically evaluate their assumptions ...Read more
Investment insights
Rate relief on the horizon? How a November cut could reshape Australian balance sheets
With unemployment edging up to a multi-year high, markets are weighing whether the Reserve Bank will pivot to a rate cut as early as November. For CFOs and CEOs, the real question isn’t if a cut ...Read more
Investment insights
J.P. Morgan unveils insights from the world's wealthiest families in 2025 report
In a world increasingly defined by rapid technological advancements and global uncertainties, J.P. Morgan has released its 2025 Principal Discussions Report, offering a unique glimpse into the minds ...Read more
Investment insights
RBA keeps the playbook open: how to navigate an “anything-can-happen” rate path
The Reserve Bank has kept its options open on interest rates, signalling neither cuts nor hikes are off the table. For boards and CFOs, that ambiguity is not a bug — it’s the game. With the cash rate ...Read more
Investment insights
Hotter CPI, cooler cuts: What the RBA pause means for balance sheets, pricing and 2025 strategy
A surprise upside in quarterly inflation has shifted the Reserve Bank of Australia’s calculus: a cut now looks less likely, and a prolonged plateau in rates more probable. For CFOs, that changes the ...Read more
